RESUMO
Background: There is a need for vaccines that can induce effective systemic, respiratory mucosal, and cellular immunity to control the COVID-19 pandemic. We reported previously that a synthetic mucosal adjuvant SF-10 derived from human pulmonary surfactant works as an efficient antigen delivery vehicle to antigen presenting cells in the respiratory and gastrointestinal tracts and promotes induction of influenza virus antigen-specific serum IgG, mucosal IgA, and cellular immunity. Methods: The aim of the present study was to determine the effectiveness of a new administration route of trans-airway (TA) vaccine comprising recombinant SARS-CoV-2 spike protein 1 (S1) combined with SF-10 (S1-SF-10 vaccine) on systemic, local, and cellular immunity in mice, compared with intramuscular injection (IM) of S1 with a potent adjuvant AddaS03™ (S1-AddaS03™ vaccine). Results: S1-SF-10-TA vaccine induced S1-specific IgG and IgA in serum and lung mucosae. These IgG and IgA induced by S1-SF-10-TA showed significant protective immunity in a receptor binding inhibition test of S1 and angiotensin converting enzyme 2, a receptor of SARS-CoV-2, which were more potent and faster achievement than S1-AddaS03™-IM. Enzyme-linked immunospot assay showed high numbers of S1-specific IgA and IgG secreting cells (ASCs) and S1-responsive IFN-γ, IL-4, IL-17A cytokine secreting cells (CSCs) in the spleen and lungs. S1-AddaS03™-IM induced IgG ASCs and IL-4 CSCs in spleen higher than S1-SF-10-TA, but the numbers of ASCs and CSCs in lungs were low and hardly detected. Conclusions: Based on the need for effective systemic, respiratory, and cellular immunity, the S1-SF-10-TA vaccine seems promising mucosal vaccine against respiratory infection of SARS-CoV-2.
Assuntos
COVID-19 , Surfactantes Pulmonares , Humanos , Animais , Camundongos , Surfactantes Pulmonares/farmacologia , SARS-CoV-2 , Interleucina-4/farmacologia , Pandemias , Imunidade nas Mucosas , Anticorpos Antivirais , Adjuvantes Imunológicos , Imunidade Celular , Imunoglobulina A/farmacologia , Imunoglobulina GRESUMO
Food allergy is one of the major existing health problems, but no effective treatment is available. In the current work, a murine model that closely mimics pathogenesis of human food allergy and its quantifiable diagnostic parameter design, even for mild hypersensitivity reactions, were established. BALB/c mice were epicutaneously sensitized with 1 mg chicken egg ovomucoid (OVM) or cow's milk casein, free of adjuvants, five times a week for two consecutive weeks. Eleven days later, allergen-specific IgG1 and IgE in serum were measured by ELISA. On day 25, 20 mg OVM or 12 mg α-casein was administered orally, and allergic reactions such as the fall in rectal temperature, symptom scores during 90-120 min, serum mast cell protease-1 and cytokine levels were monitored. The detection of mild allergic reactions due to adjuvant-free allergen sensitization and oral allergen challenge routes was amplified by the combination of oral allergen and aspirin administration simultaneously or aspirin administration within 15-30 min before an allergen challenge. Quantification of the maximum symptom score and the frequency of symptoms during the monitoring period improved evaluation accuracy of food allergy signals. Based on these results, efficacy of casein oral immunotherapy for cow's milk allergies, which are generally difficult to detect, was monitored adequately.
Assuntos
Hipersensibilidade Alimentar , Hipersensibilidade a Leite , Humanos , Feminino , Bovinos , Camundongos , Animais , Alérgenos , Caseínas , Aspirina , Modelos Animais de Doenças , Hipersensibilidade Alimentar/diagnóstico , Hipersensibilidade Alimentar/terapia , Hipersensibilidade a Leite/diagnóstico , Hipersensibilidade a Leite/terapia , Adjuvantes Imunológicos , Ovomucina , ImunoterapiaRESUMO
Conventional serum antibody titer, which expresses antibody level, does not provide antigen binding avidity of the variable region of the antibody, which is essential for the defense response to infection. Here, we quantified anti-SARS-CoV-2 antibody binding avidity to the receptor-binding domain (RBD) by competitive binding-inhibition activity (IC50) between SARS-CoV-2 S1 antigen immobilized on the DCP microarray and various RBD doses added to serum and expressed as 1/IC50 nM. The binding avidity analyzed under equilibrium conditions of antigen-antibody binding reaction is different from the avidity index measured with the chaotropic agent, such as urea, under nonequilibrium and short-time conditions. Quantitative determination of the infection-protection potential of antibodies was assessed by ABAT (antigen binding avidity antibody titer), which was calculated by the quantity (level) × quality (binding avidity) of antibodies. The binding avidity correlated strongly (r = 0.811) with cell-based virus-neutralizing activity. Maturation of the protective antibody induced by repeated vaccinations or SARS-CoV-2 infection was classified into three categories of ABAT, such as an initial, low, and high ABAT. Antibody maturity correlated with the clinical severity of COVID-19. Once a mature high binding avidity was achieved, it was maintained for at least 6-8 months regardless of the subsequent change in the antibody levels.
Assuntos
COVID-19 , Humanos , SARS-CoV-2 , Anticorpos AntiviraisRESUMO
Biapenem has been used in pediatric patients as well as adult patients; however, little information is available on dosing regimens for pediatric patients. This study examined biapenem pharmacokinetics in pediatric population and performed pharmacokinetic-pharmacodynamic analysis. Biapenem plasma concentrations from 10 pediatric patients were pharmacokinetically analyzed. A multi-regression analysis showed the pharmacokinetic parameters were affected by body weight and creatinine clearance of the patients. Using the pharmacokinetic parameters, a Monte Carlo simulation predicted the probabilities of attaining the pharmacodynamic target (40% of the time above the minimum inhibitory concentration for the bacterium). In the case of about 20 kg, biapenem regimens of 5 mg/kg b.i.d. and 10 mg/kg b.i.d. provided sufficient target attainment probabilities against Streptococcus pneumoniae and Pseudomonas aeruginosa isolates, respectively. Our results should provide a PK-PD-based guidance for rationalizing biapenem regimen according to the body weight and renal function of a pediatric patient and the specific bacterium suspected.
Assuntos
Anti-Infecciosos/administração & dosagem , Tienamicinas/administração & dosagem , Adolescente , Anti-Infecciosos/farmacocinética , Anti-Infecciosos/farmacologia , Peso Corporal , Criança , Pré-Escolar , Creatinina/urina , Farmacorresistência Bacteriana , Feminino , Humanos , Masculino , Taxa de Depuração Metabólica , Modelos Biológicos , Método de Monte Carlo , Pseudomonas aeruginosa/efeitos dos fármacos , Análise de Regressão , Streptococcus pneumoniae/efeitos dos fármacos , Tienamicinas/farmacocinética , Tienamicinas/farmacologiaRESUMO
A simple and rapid HPLC method that includes ultrafiltration to remove plasma and peritoneal fluid protein was developed to determine doripenem concentrations in human plasma and peritoneal fluid. Doripenem was stabilized by immediate mixing of the plasma or peritoneal fluid with 1M 3-morpholinopropanesulfonic acid buffer (pH 7.0) (1:1). Doripenem and an internal standard were detected by measuring their ultraviolet absorbance at 300 nm. The calibration curves for doripenem in human plasma and peritoneal fluid were linear from 0.05 to 100 microg/mL. For plasma, both the intra- and the interday precision were less than 3.41% (CV), and the accuracy was between 97.4 and 101.7% above 0.05 microg/mL. For peritoneal fluid, the intra- and the interday precision were less than 2.98% (CV), and the accuracy was between 94.4 and 103.9% above 0.05 microg/mL. The limit of detection was 0.02 microg/mL in both plasma and peritoneal fluid. The assay has been applied to the therapeutic drug monitoring of doripenem in both plasma and peritoneal fluid.
Assuntos
Líquido Ascítico/química , Carbapenêmicos/análise , Cromatografia Líquida de Alta Pressão/métodos , Espectrofotometria Ultravioleta/métodos , Carbapenêmicos/sangue , Carbapenêmicos/farmacocinética , Doripenem , Humanos , Reprodutibilidade dos TestesRESUMO
A high-performance liquid chromatography (HPLC) method using ultrafiltration to pretreat peritoneal fluid and bile samples is developed to measure meropenem and biapenem concentrations in human peritoneal fluid and bile. Meropenem or biapenem in peritoneal fluid or bile samples is stabilized by mixing with 1 mol/L 3-morpholinopropanesulfonic acid buffer (pH 7.0) (1:1). The mixture is transferred to a Nanosep 10K centrifugal filter device; after centrifugation, the filtrate is subjected to reversed-phase HPLC, and the eluate is monitored at 300 nm. No interference from endogenous substances is observed. The lower limits of quantification are 0.05 microg/mL for peritoneal fluid and 0.1 microg/mL for bile. The new method has been applied to comparative site-specific-pharmacokinetic investigations in surgery patients.